Kamada (KMDA) Times Interest Earned (2012 - 2026)
Kamada's (KMDA) quarterly Times Interest Earned came in at 25.63 in Q2 2026, down 105.08% on a YoY basis from 505.07 in Q2 2025, and up 30.69% quarter-over-quarter from 36.98 in Q1 2026.
Powered by 
Analysis
Kamada (KMDA) Times Interest Earned (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Times Interest Earned for 15 consecutive years, with 25.63 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Times Interest Earned fell 105.08% year-over-year to 25.63; the trailing twelve-month figure through Jun 2026 stood at 26.79 (up 43.33% YoY), and the FY2025 full-year result was 30.36, changed 0.06% from the prior year.
- Times Interest Earned improved to 25.63 in Q2 2026 per KMDA's latest filing, from 36.98 in the prior quarter.
- Across five years, Times Interest Earned topped out at 505.07 in Q2 2025 and bottomed at 40.6 in Q1 2025.
- Historically, Times Interest Earned has averaged 17.33 across 5 years, with a median of 0.56 in 2022.
- The sharpest annual moves came in 2024 and 2025: Times Interest Earned tumbled 2075.74% in 2024, then soared 10207.4% in 2025.
- Over 5 years, Times Interest Earned stood at 3.75 in 2022, then plunged by 132.95% to 1.23 in 2023, then sank by 2075.74% to 26.87 in 2024, then jumped by 48.97% to 13.71 in 2025, then sank by 86.96% to 25.63 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered 25.63, 36.98, and 13.71 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 5.22 |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -42.08 |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 117.59 |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 493.00 |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 2.82 |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Kamada | 473.57 Mn | 403.43 Mn | 22.47 Mn | 25.63 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -25.63 |
| Mar 31, 2026 | -36.98 |
| Dec 31, 2025 | -13.71 |
| Sep 30, 2025 | -35.37 |
| Jun 30, 2025 | 505.07 |
| Mar 31, 2025 | -40.60 |
| Dec 31, 2024 | -26.87 |
| Sep 30, 2024 | -31.70 |
| Jun 30, 2024 | 4.90 |
| Mar 31, 2024 | 2.52 |
| Dec 31, 2023 | -1.23 |
| Sep 30, 2023 | 4.07 |
| Jun 30, 2023 | 3.62 |
| Mar 31, 2023 | 0.14 |
| Dec 31, 2022 | 3.75 |
| Sep 30, 2022 | 1.24 |
| Jun 30, 2022 | -1.42 |
| Mar 31, 2022 | 0.12 |
| Dec 31, 2021 | -2.42 |
| Sep 30, 2021 | -19.14 |